Maverix Private Equity hires Wasserman as managing partner

Maverix Private Equity, a Toronto-based private equity firm that is marketing a debut $500 million growth fund, hired Michael Wasserman as a managing partner.

Maverix Private Equity, a Toronto-based private equity firm that is marketing a debut $500 million growth fund, hired Michael Wasserman as a managing partner. Wasserman joins from HIG BioHealth Partners, where he was a managing director. Maverix also hired Peter Hass, previously with Mattamy Asset Management and OMERS Growth Equity, as an associate partner, and added Jonathan Goodman, CEO of Knight Therapeutics, to its advisory board.


TORONTO, May 3, 2021 /CNW/ – Maverix Private Equity, a Toronto-based private equity firm which recently announced an inaugural USD $500 million growth-fund, has today announced the addition of Michael Wasserman as a Managing Partner, joining Founder John Ruffolo and Mark Maybank. Michael is returning to Canada after 17 years at H.I.G Capital Management, a leading global private equity investment firm with more than $44 billion of equity capital under management. Most recently, Michael was a Managing Director of H.I.G. BioHealth Partners, the firm’s dedicated healthcare investment fund, where Michael sourced, executed and managed a diverse investment portfolio of healthcare business across stages, sectors and geographies. Michael remains a Senior Advisor with H.I.G. In addition to his firm-wide responsibilities, Michael will be leading Maverix’s investments in Healthcare and Wellness, one of the firm’s core investment themes.

“I could not be prouder to be coming home to join this talented group of investors and entrepreneurs”, said Michael Wasserman. “The progress and evolution of the Canadian innovation ecosystem in recent years has been nothing short of remarkable. Maverix is uniquely positioned to help catalyze the growth of disruptive Canadian businesses and global leaders and I am truly humbled and excited to be part of this compelling effort.”

In addition to Michael Wasserman, Peter Hass has also joined Maverix as Associate Partner. Peter will be leading investment deal execution including financial modelling and leading due diligence. Peter will also work closely with portfolio companies in strategic and financial management as well as the evaluation of organic and inorganic growth opportunities. Peter is an experienced private equity investor, having formerly worked at both Mattamy Asset Management and OMERS Growth Equity.

Finally, Jonathan Goodman, co-founder, President and CEO of publicly traded Paladin Labs Inc., which was acquired in 2014 by Endo International In. (NASDAQ: ENDP) for $3.2 billion will be joining the Maverix Advisory board as its 6th member. The Maverix Advisory Board represents a who’s who of successful Canadian entrepreneurs and business leaders, who share a similar mission, to help build the next wave of disruptive Canadian businesses.

Under Mr. Goodman`s leadership, $1.50 invested in Paladin at its founding was worth $142 nineteen years later. The same day that Paladin was sold, Mr. Goodman started a second publicly-traded specialty pharmaceutical company, Knight Therapeutics Inc. (TSX: GUD), which has now raised $685 million of equity in 5 rounds of financing all at increasing valuations. Since inception in February 2014, Knight has generated over $220 million of net income. For the last 25 years, Mr. Goodman has devoted 15% of his time on Tikkun Olam, which has included fielding the largest team in the Province of Quebec for the Ride to Conquer Cancer for 7 consecutive years to filling Place des Arts for the Ted Wise ORT/Jewish Education Gala for 6 consecutive years raising $10+ million to support Jewish education.

Maverix Private Equity is a Toronto-based private equity firm. It is led by an experienced and talented team with the background, network, and track record necessary to successfully execute on an investment strategy of technology-enabled growth and disruption. Maverix is currently investing out of its inaugural fund, the Maverix Growth Equity Fund I, of USD$500M. Maverix targets North American companies with rapidly growing revenue and evidence of a profitable business model. Its target cheque size is expected to average USD$50M for meaningful minority positions in portfolio companies.
For more information on Product: